Skip to main navigation Skip to search Skip to main content

Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission

  • Roni Shouval
  • , Myriam Labopin
  • , David Bomze
  • , Gabriela M. Baerlocher
  • , Saveria Capria
  • , Didier Blaise
  • , Mathias Hänel
  • , Edouard Forcade
  • , Anne Huynh
  • , Riccardo Saccardi
  • , Giuseppe Milone
  • , Tsila Zuckerman
  • , Péter Reményi
  • , Jurjen Versluis
  • , Jordi Esteve
  • , Norbert Claude Gorin
  • , Mohamad Mohty
  • , Arnon Nagler
  • Tel Aviv University
  • Sheba Medical Center at Tel Hashomer
  • Acute Leukemia Working Party of EBMT
  • Sorbonne Université
  • University of Bern
  • University of Rome La Sapienza
  • Institut Paoli Calmettes
  • Hospital Chemnitz
  • Bordeaux University Hospital
  • CHU de Toulouse
  • Azienda Ospedaliera Careggi
  • Ospedale Ferrarotto
  • Rambam Health Care Campus
  • St. István and St. László Hospital of Budapest
  • Erasmus University Rotterdam
  • IDIBAPS

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

FLT3-ITD and NPM1 mutation refine prognostic stratification in acute myeloid leukemia (AML) with intermediate-risk cytogenetics. However, data on their role in patients undergoing autologous stem cell transplantation (Auto-SCT) as post-remission therapy (PRT) are limited. We therefore sought to retrospectively evaluate the role of FLT3-ITD and NPM1 in a cohort of AML patients (n = 405) with intermediate-risk cytogenetics, autografted in first complete remission (CR1). Patients were transplanted between 2000 and 2014 and reported to the European Society for Blood and Marrow Transplantation (EBMT) registry. Leukemia-free survival (LFS) was the primary outcome. Median follow-up was 5.5 years. FLT3-ITDneg/NPM1WT was the leading molecular subtype (50%), followed by FLT3-ITDneg/NPM1mut (30%). In the univariate analysis, molecular subtype was associated with LFS, overall survival (OS), and relapse incidence (RI) (p < 0.001); 5-year LFS: FLT3-ITDneg/NPM1mut 62%, FLT3-ITDpos/NPM1mut 38%, FLT3-ITDneg/NPM1WT 32%, and FLT3-ITDpos/NPM1WT 21%. At 5 years, OS and RI in the FLT3-ITDneg/NPM1mut subtype were 74% and 35%, respectively. The corresponding OS and RI in other subtypes were below 48% and over 57%. In a Cox multivariable model, molecular subtype was the strongest predictor of LFS, OS, and relapse. In conclusion, AML patients with intermediate-risk cytogenetics and FLT3-ITDneg/NPM1mut experience favorable outcomes when autografted in CR1, suggesting that Auto-SCT is a valid PRT option.

Original languageEnglish
Pages (from-to)2244-2253
Number of pages10
JournalBone Marrow Transplantation
Volume55
Issue number12
DOIs
StatePublished - Dec 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Funding

Acknowledgements The study was supported by the Varda and Boaz Dotan Research Center in Hemato-oncology, Idea Award Research Grant, Tel-Aviv University.

Funders
Tel Aviv University
Varda and Boaz Dotan Research Center for Hemato-Oncology Research, Tel Aviv University

    Fingerprint

    Dive into the research topics of 'Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission'. Together they form a unique fingerprint.

    Cite this